Table 5.

Clinicopathological and biological factors affecting OS and PFS rates of patients with medulloblastoma by univariate and multivariate analyses. Abbreviations: CI = confidence interval; D/N = desmoplastic/nodular; GTR = gross total resection; HR = hazard ratio; LC/A = large cell/anaplastic; OS = overall survival; PFS = progression‐free survival

	OS				PFS
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age	1.015 (0.969–1.063)	0.526	0.968 (0.902–1.038)	0.359	1.009 (0.965–1.056)	0.686	0.968 (0.910–1.031)	0.313
Histologic type		0.287		0.140		0.729		0.202
Classic
D/N	0.541 (0.132–2.218)	0.392	0.138 (0.011–1.774)	0.164	0.746 (0.279–1.991)	1.000	0.280 (0041–1.910)	0.274
LC/A	1.632 (0.554–4.805)	0.310	1.688 (0.276–10.328)	1.000	1.205 (0.483–3.005)	1.000	1.548 (0.301–7.960)	1.000
CTNNB1
Mutant (vs. wild)	0.247 (0.037–2.028)	0.205	0.627 (0.065–6.019)	0.627	0.410 (0.097–1.721)	0.223	0.892 (0.169–4.721)	0.893
Ror2 mRNA
High expression (vs. low)	0.388 (0.152–0.995)	0.049	0.179 (0.036–0.879)	0.034	0.360 (0.152–0.851)	0.020	0.213 (0.054–0.845)	0.213
Wnt5a mRNA
High expression (vs. low)	0.759 (0.309–1.863)	0.547	2.755 (0.524–14.488)	0.232	0.748 (0.337–1.661)	0.476	1.556 (0.410–5.902)	0.516
MYCC
Amplification (vs. no amplification)	1.039 (0.386–2.800)	0.939	0.838 (0.131–5.362)	0.852	1.039 (0.386–2.800)	0.939	0.973 (0.231–4.099)	0.970
MYCN
Amplification (vs. no amplification)	1.558 (0.662–3.664)	0.310	2.550 (0.873–7.447)	0.087	1.824 (0.864–3.849)	0.761	4.157 (0.906–10.757)	0.083
Metastasis
Metastasis (vs. no metastasis)	2.756 (1.143–6.642)	0.024	3.489 (0.968–12.574)	0.056	0.870 (0.355–2.131)	0.296	1.700 (0.508–5.685)	0.389
Primary surgery type
Non‐GTR (vs. GTR)	2.522 (1.142–5.570)	0.022	0.966 (0.526–3.652)	0.966	2.887 (1.410–5.912)	0.004	1.469 (0.500–4.317)	0.484
Postoperative treatment
Yes (vs. No)	0.062 (0.019–0.205)	<0.001	0.047 (0.008–0.269)	0.001	0.105 (0.034–0.325)	<0.001	0.147 (0.032–0.678)	0.014